Neupogen (Filgrastim)

Filgrastim is a recombinant form of human granulocyte colony‑stimulating factor. It binds to the G‑CSF receptor on bone‑marrow progenitor cells, activating signaling pathways that stimulate the proliferation, differentiation, and survival of neutrophil precursors, thereby increasing the number of mature neutrophils released into the bloodstream.

The dose of Neupogen is individualized. A qualified prescriber determines the amount, frequency, and route of administration based on the specific indication, patient weight, renal function, and clinical response. Dosing details are provided in the prescribing information and should be followed exactly as directed by the healthcare professional.

Neupogen is classified as Pregnancy Category C, indicating that risk to the fetus cannot be ruled out. It should only be used when the potential maternal benefit justifies the potential risk. Limited data are available for breastfeeding; the decision to continue nursing should be made after discussing risks and benefits with a qualified clinician.

To request Neupogen, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling), and any necessary import documentation.

The primary alternative to filgrastim is pegfilgrastim, a pegylated, long‑acting form of G‑CSF that requires only a single injection per chemotherapy cycle. Filgrastim (Neupogen) has a shorter half‑life and is typically administered daily for several days. Choice between the two depends on clinical protocol, patient convenience, cost considerations, and physician preference.

Neupogen must be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the vial in its original packaging, protect it from light, and avoid freezing. Do not shake the solution. Before use, allow the product to reach room temperature if required, and inspect for particulate matter or discoloration. Follow aseptic technique during preparation and administration.

Neupogen is supplied as a sterile solution for injection and is administered by a qualified healthcare professional either subcutaneously or intravenously, depending on the clinical indication and treatment protocol. The injection site is typically the abdomen, thigh, or upper arm for subcutaneous use. Intravenous administration is performed under controlled conditions in a clinical setting.

Serious adverse events include splenic rupture, which may present as sudden abdominal pain; acute respiratory distress syndrome (ARDS), characterized by severe shortness of breath; and anaphylactic reactions, which can cause hives, swelling, and airway compromise. Patients should be monitored closely for these signs, and immediate medical attention is required if they occur.

Neupogen is contraindicated in individuals with a known hypersensitivity to filgrastim or any of its excipients. It should also be avoided in patients who have experienced severe allergic reactions to other granulocyte colony‑stimulating factors. Caution is advised for patients with uncontrolled splenomegaly, active infections, or those receiving concurrent myeloid growth factors unless specifically directed by a physician.